Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Recruiting now · Phase 2
Conditions studied: Pancreas Cancer
In brief
Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
Key facts
- Study ID
- NCT06050317
- Run by
- Shandong Cancer Hospital and Institute
- People needed
- 25
- Starts
- 2023-08-18
- Expected to finish
- 2026-08-18
- Last updated by the study team
- 2026-05-01
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ECOG PS 0-1
- Pathological tissue-confirmed unresectable locally advanced pancreatic cancer
- Pancreatic cancer patients who have not received systemic anti-tumor therapy
- Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards
- A life expectancy of > 3 months
- Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells/L, platelets ≥ 75×109 cells/L, hemoglobin ≥ 9.0 g/dl
- AST<2.5 × ULN(Upper Limit of Normal), ALT<2.5 × ULN,creatinine ≤1.5xULN, total bilirubin < ≤1.5 X ULN.
You may not qualify if…
- Diagnosed with other malignant diseases other than pancreatic cancer within three years before enrollment
- Patients who are currently participating in interventional clinical research treatment or have received other research drugs or used research devices within four weeks before enrollment
- Patients who have previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors
- Patients who have received systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment
- Abnormal results of blood routine examinations and liver and kidney and coagulation tests
- Abnormal function of major organs (14 days before enrollment)
- Women who are pregnant
- Inability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.
Where it is running
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute — Jinan, Shandong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.